Skip to main content
logo
Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
12.61
+1.01 (8.71%)
Aug 19, 2026, 9:57 AM EDT - Market open

Intellia Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
59.5167.6757.8836.2852.1233.05
Revenue Growth
12.58%16.92%59.55%-30.40%57.69%-43.01%
Cost of Revenue
282.32324.45406.91435.07419.98229.81
Gross Profit
-222.82-256.78-349.04-398.79-367.86-196.75
Selling, General & Admin
200.66184.21185.23116.590.3171.1
Operating Expenses
200.66184.21185.23116.590.3171.1
Operating Income
-423.48-440.99-534.26-515.29-458.16-267.85
Interest & Investment Income
24.1929.247.8149.838.541.28
Earnings From Equity Investments
----15.63-11.08-1.33
EBT Excluding Unusual Items
-399.29-411.8-486.46-481.09-460.7-267.89
Gain (Loss) on Sale of Investments
-0.69-0.9-32.57---
Other Unusual Items
----0.1-13.49-
Pretax Income
-399.98-412.69-519.02-481.19-474.19-267.89
Net Income
-399.98-412.69-519.02-481.19-474.19-267.89
Net Income to Common
-399.98-412.69-519.02-481.19-474.19-267.89
Net Income Growth
------
Shares Outstanding (Basic)
12010899897771
Shares Outstanding (Diluted)
12010899897771
Shares Change
16.63%9.64%11.35%15.33%8.57%26.63%
EPS (Basic)
-3.34-3.81-5.25-5.42-6.16-3.78
EPS (Diluted)
-3.34-3.81-5.25-5.42-6.16-3.78
EPS Growth
------
Free Cash Flow
-348.69-395.87-354.66-408.07-346.85-237.79
Free Cash Flow Per Share
-2.92-3.65-3.59-4.60-4.51-3.35
Operating Margin
-711.66%-651.67%-923.10%-1420.51%-879.04%-810.37%
Profit Margin
-672.16%-609.85%-896.77%-1326.51%-909.78%-810.49%
Free Cash Flow Margin
-585.97%-584.99%-612.78%-1124.94%-665.46%-719.41%
EBITDA
-414.4-431.22-523.98-506.32-450.59-260.96
D&A For EBITDA
9.089.7710.298.987.576.89
EBIT
-423.48-440.99-534.26-515.29-458.16-267.85
SEC Filings: 10-K · 10-Q